APOL4

Across TCGA pan-cancer cohorts, APOL4 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated APOL4 data layer compared with 27 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher APOL4 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated APOL4 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

READ, ACC, and PRAD are the cancer types where APOL4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	DFS	Median	III,IV	0.255	0.757	.008	15	view →
ACC	DFS	Median	All	0.066	0.667	.002	12	view →
PRAD	DFS	Median	All	0.085	0.774	.007	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
COAD	OS	Median	All	0.231	0.687	.009	4	view →
SKCM	DFS	Median	II,III,IV	1.000	0.669	.028	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

APOL4–READ (DFS)

Open the READ breakdown →